National cohort analysis reveals an L-shaped association between vigorous intermittent lifestyle physical activity and mortality risk in US adults, suggesting significant health benefits.
Background Vigorous intermittent lifestyle physical activity (VILPA) completed through normal daily living may offer a time-efficient avenue to accrue physical activity in a behaviorally sustainable manner. However, no research to date has explored its association with mortality in a nationally representative population. Objectives To examine the dose-response association between VILPA and mortality risk in a nationally representative sample of US adults. Methods This study included a nationally representative sample of 3,293 US adults from the 2011-14 National Health and Nutrition Examination Survey (NHANES) who self-reported no participation in structured exercise (52.3% female; mean age: 50.7 [SD: 16.6 years]. The dose-response relationship between VILPA and all-cause mortality was estimated using multivariable-adjusted cubic splines. Average daily frequency (bouts/day) and duration (minutes/day) of VILPA bouts lasting up to one minute were measured using a wrist-worn accelerometer. Results Over the mean (SD) 6.7 (1.4) year follow-up period, 290 all-cause mortality events occurred. Compared to the referent point (0 bouts per day), there was an L-shaped dose-response association where the median frequency (5.3 bouts per day) was associated with a 44% lower risk of all-cause mortality (HR: 0.56; 95% CI: 0.39, 0.82). The dose response curve was less steep beyond approximately 8 bouts per day (HR: 0.46; 95% CI: 0.28, 0.77). Daily duration of VILPA demonstrated a near-linear association with all-cause mortality risk with a median duration of 1.1 minutes associated with an HR of 0.61 (95% CI: 0.42, 0.88). Conclusions Short bursts of intermittent vigorous physical activity were associated with meaningful health benefits in a nationally representative sample of US adults. Future trials are warranted to investigate the effectiveness and feasibility of VILPA-based interventions.
No takes yet. Share an insight, caveat, or question.
Koemel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: